Liquidia Corporation (LQDA) Stock Forecast and Price Target (2026)

The average target of $74.67 sits well above the $27.70 price, +169.6%. The median is $62.50, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.

The published targets span $40.00 to $130.00. That gap is 121% of the average target, which counts as wide disagreement. A spread that wide is the most informative number on this page: analysts who all follow the company closely cannot agree within a factor that large, which means the outcome genuinely depends on assumptions nobody can settle yet.

The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the LQDA is it a buy page.

The most recent individual rating action we hold on LQDA is around 24 months old. We do not show it. A price target set that long ago tells you nothing about today and would be actively misleading printed next to the current price. The consensus figures above are current as of October 2026; the per-firm history is not, so treat the coverage on this name as thin.

Of the analysts with a published rating, 5 say buy, 3 say hold, and 0 say sell, so 63% carry a buy. That buy share has fallen over the last three months, so sentiment is drifting more negative.

Read the distribution rather than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.

• It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
• The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
• Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
• Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering LQDA do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

On the figures we hold as of October 2026, LQDA trades at about 19.8 times trailing earnings and 11.5 times forward earnings. A forward multiple below the trailing one means the market expects earnings to grow, and the size of that gap is roughly how much growth is already in the price.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Liquidia Corporation can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are Yutrepia commercial ramp, Swing to profitability, Expanding indications and label reach. The risk cited most often against it is liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, in a single therapeutic area, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the LQDA is it a buy page. This page deliberately stops at the numbers.